CGCansu Arslantürk Güneysu

Cansu Arslantürk Güneysu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cansu Arslantürk Güneysu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Do age at disease diagnosis and age at symptom onset affect cognitive functions in Sjögren's syndrome?

    by Gamze Dilek, Mehtap Kalçık Unan, Seyyid Bilal Açıkgöz, Tamer Acat, Nilay Erdik, Sümeyye Merve Türk, Damla Karataş, Cansu Arslantürk Güneysu, Gökhan Yavuzbilge, Sedat Özmen, et al.

    Objectives: In this study, we aimed to investigate the relationship between the age of onset of disease symptoms, the age at diagnosis, and cognitive function in patients with primary Sjögren's syndrome (pSS). Methods: Sixty-two patients diagnosed with pSS who presented to the Sakarya Training and Research Hospital Internal Medicine Rheumatology outpatient clinic between November 2021 and November 2022 were included in the study. Parameters such as age at diagnosis, age at symptom onset, fibromyalgia status, Beck Depression Inventory (BDI) score, Beck Anxiety Inventory (BAI) score, insomnia, fatigue, learning disability, and number of comorbidities were recorded. The Montreal Cognitive Assessment (MoCA) score was used to evaluate cognitive function. The scale ranges from 0 to 30, with a threshold value set at 21. Scores of 21 and above were considered normal. Independent samples t-tests, Mann-Whitney U tests, and chi-square tests were used for data comparison. Results: Patients with MoCA values less than 21 were significantly older. In the study, the age at symptom onset for patients with a MoCA score<21 was significantly higher than for those with a MoCA score ≥ 21 (p<0.05). Similarly, the age at diagnosis for patients with MoC<A values<21 was significantly higher than for those with MoCA values ≥ 21 (p<0.05). The impaired group (MoCA<21) comprised 20 individuals, representing 32.2%±3% of the cohort, while the non-impaired group consisted of 42 individuals, accounting for 67.7%±4% of the patients (p<0.001). A negative correlation was detected between age at the onset of symptoms (r=-0.376, p=0.003), disease diagnosis age (r=-0.297, p=0.019), and the MoCA value. Conclusion: In our study, a negative correlation was found between age at the onset of symptoms, age at diagnosis, and MoCA values. Early diagnosis and treatment of SS can minimize cognitive dysfunction that may develop during the disease process. Maintaining high cognitive function will positively affect the quality of life.

  • Open Access

    Do age at disease diagnosis and age at symptom onset affect cognitive functions in Sjögren's syndrome?

    by Gamze Dilek, Mehtap Kalçık Unan, Seyyid Bilal Açıkgöz, Tamer Acat, Nilay Erdik, Sümeyye Merve Türk, Damla Karataş, Cansu Arslantürk Güneysu, Gökhan Yavuzbilge, Sedat Özmen, et al.

    Objectives: In this study, we aimed to investigate the relationship between the age of onset of disease symptoms, the age at diagnosis, and cognitive function in patients with primary Sjögren's syndrome (pSS). Methods: Sixty-two patients diagnosed with pSS who presented to the Sakarya Training and Research Hospital Internal Medicine Rheumatology outpatient clinic between November 2021 and November 2022 were included in the study. Parameters such as age at diagnosis, age at symptom onset, fibromyalgia status, Beck Depression Inventory (BDI) score, Beck Anxiety Inventory (BAI) score, insomnia, fatigue, learning disability, and number of comorbidities were recorded. The Montreal Cognitive Assessment (MoCA) score was used to evaluate cognitive function. The scale ranges from 0 to 30, with a threshold value set at 21. Scores of 21 and above were considered normal. Independent samples t-tests, Mann-Whitney U tests, and chi-square tests were used for data comparison. Results: Patients with MoCA values less than 21 were significantly older. In the study, the age at symptom onset for patients with a MoCA score<21 was significantly higher than for those with a MoCA score ≥ 21 (p<0.05). Similarly, the age at diagnosis for patients with MoC<A values<21 was significantly higher than for those with MoCA values ≥ 21 (p<0.05). The impaired group (MoCA<21) comprised 20 individuals, representing 32.2%±3% of the cohort, while the non-impaired group consisted of 42 individuals, accounting for 67.7%±4% of the patients (p<0.001). A negative correlation was detected between age at the onset of symptoms (r=-0.376, p=0.003), disease diagnosis age (r=-0.297, p=0.019), and the MoCA value. Conclusion: In our study, a negative correlation was found between age at the onset of symptoms, age at diagnosis, and MoCA values. Early diagnosis and treatment of SS can minimize cognitive dysfunction that may develop during the disease process. Maintaining high cognitive function will positively affect the quality of life.

  • Open Access

    The relationship between neuropathic pain and lower urinary tract symptom scores in patients with primary Sjögren’s syndrome

    by Nilay Erdik, Anil Erdik, Damla Kizil, Gokhan Yavuzbilge, Sumeyye Merve Turk, Cansu Arslanturk Guneysu, Abbas Karakurt, Sedat Ozmen, Emel Gonullu

    To evaluate the effect of neuropathic pain on lower urinary tract symptoms (LUTS) scores in patients with primary Sjögren’s syndrome (pSS). Seventy-two patients diagnosed with pSS were included in the study. The patients with pSS were divided into two groups according to the presence/absence of neuropathic pain. The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) questionnaire was recorded assess neuropathic pain. LUTS was evaluated using the International Prostate Symptom Score (IPSS), International Incontinence Consultation Questionnaire Short Form (ICIQ-SF) and Overactive Bladder Questionnaire (OAB-V8). The mean age of the patients was 52.4 ± 11.2 years. Neuropathic pain was recorded in 21 (29.2%) patients. Among the patients, the number of patients with mild symptoms was recorded as 41 (56.9%), moderate symptoms in 25 (34.7%), and severe symptoms in 6 (8.3%) according to IPSS. IPSS and IPSS voiding subscores were statistically significantly higher in patients with neuropathic pain than non-neuropathic pain group (p = 0.035; p = 0.001, respectively). Although ICIQ-SF, OAB-V8 and IPSS storage subscores were found to be higher in patients with neuropathic pain group, there was no statistically significant difference between the groups (p = 0.299; p = 0.283; p = 0.237, respectively). Neuropathic pain concomitant with PSS patients may negatively affect bladder voiding functions.